--- title: "Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day" type: "News" locale: "en" url: "https://longbridge.com/en/news/286471268.md" description: "Inovio Pharmaceuticals Inc. (INO) shares rose 1.49% to $1.36 on a positive trading day, breaking a three-day losing streak. The NASDAQ Composite Index increased by 0.88%, while the Dow Jones Industrial Average rose by 0.75%. Inovio's stock remains 54.35% below its 52-week high of $2.98. Competitors had mixed results, with Johnson & Johnson up 0.16%, Statera Biopharma unchanged, and Pfizer down 0.81%. Trading volume was 2.5 million, below the 50-day average of 2.6 million." datetime: "2026-05-14T21:24:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286471268.md) - [en](https://longbridge.com/en/news/286471268.md) - [zh-HK](https://longbridge.com/zh-HK/news/286471268.md) --- # Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Inovio Pharmaceuticals Inc. (INO) rallied 1.49% to $1.36 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 0.88% to 26,635.22 and the Dow Jones Industrial Average rising 0.75% to 50,063.46. The stock's rise snapped a three-day losing streak. Inovio Pharmaceuticals Inc. closed 54.35% short of its 52-week high of $2.98, which the company reached on September 9th. The stock outperformed some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 0.16% to $230.80, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. (PFE) fell 0.81% to $25.75. Trading volume (2.5 M) remained 129,762 below its 50-day average volume of 2.6 M. Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 05-14-26 1724ET ### Related Stocks - [INO.US](https://longbridge.com/en/quote/INO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md) - [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md) - [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [FDS.US](https://longbridge.com/en/quote/FDS.US.md) ## Related News & Research - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md) - [](https://longbridge.com/en/news/286807703.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [](https://longbridge.com/en/news/286273737.md) - [](https://longbridge.com/en/news/286601439.md)